<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">PI</journal-id><journal-title-group><journal-title>Pharmacy Information</journal-title></journal-title-group><issn pub-type="epub">2160-441X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/PI.2020.91003</article-id><article-id pub-id-type="publisher-id">PI-33860</article-id><article-categories><subj-group subj-group-type="heading"><subject>PI20200100000_40134839.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  基于网络药理学探讨葛根解酒的作用机制
  Exploring the Mechanism of Gegen Hangover Based on Network Pharmacology
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>郁郁</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>黄</surname><given-names>旭龙</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>罗</surname><given-names>覃</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>谭</surname><given-names>洋</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邓</surname><given-names>先波</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>江</surname><given-names>来</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>慧</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>祥培</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>贵州中医药大学药学院，贵州 贵阳</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>12</day><month>12</month><year>2019</year></pub-date><volume>09</volume><issue>01</issue><fpage>17</fpage><lpage>26</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：运用网络药理学的方法，预测葛根的活性成分和作用靶点，揭示葛根解酒的分子作用机制。方法：通过中药系统药理学数据库(TCMSP)检索葛根中所含的全部化学成分，以ADME参数(OB ≥ 30%和 DL ≥ 0.15)，筛选具有活性的化学成分，并查找活性化学成分对应的靶点蛋白，建立靶点数据集；使用Cytoscape3.6.1软件构建“活性成分–靶点–疾病”复杂网络关系图；通过生物学信息注释数据库(DAVID)进行GO生物功能富集分析和KEGG通路富集分析，探明葛根解酒的作用机制。结果：共检索出18个化合物，其中4个化学成分为活性化合物；共检索出92个作用靶点。通过网络拓扑特征评价，筛选出8个潜在作用靶点与葛根解酒的作用机制最为密切；利用DAVID数据库对潜在作用靶点进行基因GO功能富集分析和KEGG通路富集分析，筛选出35个生物过程和28条信号通路参与葛根解酒的作用。其中与葛根解酒较为密切的信号通路包括神经活性配体–受体相互作用、钙信号途径、胆碱能突触、心肌细胞中的肾上腺素信号、PI3K-AKT信号通路、VEGF信号通路、p53信号通路、NAFLD等信号通路，同时其主要涉及的生物过程包括雌二醇反应、突触传递、胆碱能、腺苷酸环化酶抑制G蛋白偶联乙酰胆碱受体信号通路、磷脂酶C激活G蛋白偶联乙酰胆碱受体信号通路、γ-氨基丁酸信号通路、RNA聚合酶II启动子转录的阳性调控作用、细胞色素c激活参与凋亡过程的半胱氨酸型内肽酶活性等，从而发挥多成分、多靶点、多途径解酒的生物学效应。结论：网络药理学为葛根解酒的作用机制提供了研究方向及科学依据。 Objective: To predict the active constituents and targets of Radix Puerariae by using network pharmacology, and to reveal the molecular mechanism of Gegen hangover. Methods: All the chemical components contained in Radix Puerariae were searched by the Chinese Medicine System Pharmacology Database (TCMSP). The active chemical constituents were screened by ADME parameters (OB ≥ 30% and DL ≥ 0.15), and the target proteins corresponding to the active chemical com-ponents were searched to establish the target data set. Cytoscape3.6.1 software was used to construct the complex network diagram of “active ingredient - target – disease”. The GO biological function enrichment analysis and KEGG pathway enrichment analysis were carried out through the annotation database of biological information (DAVID) to explore the mechanism of Gegen antidotes. Results: A total of 18 compounds were retrieved, 4 of which were active compounds; a total of 92 targets were retrieved. Through the evaluation of network topological characteristics, the screening of 8 potential targets was the most closely related to Gegen hangover. Using the DAVID database to analyze the potential target targets for gene GO function enrichment and KEGG pathway enrichment, 35 were screened. Biological processes and 28 signaling pathways are involved in the role of Pueraria hangover. The signaling pathways that are more closely related to Pueraria hangover include neuroactive ligand-receptor interaction, calcium signaling pathway, cholinergic synapse, adrenergic signal in cardiomyocytes, PI3K-AKT signaling pathway, VEGF signaling pathway, p53 signal pathways, signaling pathways such as NAFLD, and its main biological processes include estradiol response, synaptic transmission, cholinergic, adenylate cyclase inhibition of G protein- coupled acetylcholine receptor signaling pathway, and phospholipase C activation G protein- coupled acetylcholine receptor signaling pathway, γ-aminobutyric acid signaling pathway, positive regulation of RNA polymerase II promoter transcription, cytochrome c activation, and cysteine-type endopeptidase activity involved in apoptosis, thereby exerting the biological effects of multi-component, multi-target, multi-channel hangover. Conclusion: Network pharmacology provides research direction and scientific basis for the mechanism of Gegen hangover. 
  
 
</p></abstract><kwd-group><kwd>葛根，活性成分，解酒，网络药理学，作用机制, Pueraria Lobata</kwd><kwd> Active Ingredient</kwd><kwd> Hangover</kwd><kwd> Network Pharmacology</kwd><kwd> Mechanism of Action</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>基于网络药理学探讨葛根解酒的作用机制<sup> </sup></title><p>陈郁郁，黄旭龙，罗覃，谭洋，邓先波，江来，杨慧，王祥培<sup>*</sup></p><p>贵州中医药大学药学院，贵州 贵阳</p><disp-formula id="hanspub.33860-formula42"><graphic xlink:href="//html.hanspub.org/file/3-1710207x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2019年12月18日；录用日期：2020年1月1日；发布日期：2020年1月8日</p><disp-formula id="hanspub.33860-formula43"><graphic xlink:href="//html.hanspub.org/file/3-1710207x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：运用网络药理学的方法，预测葛根的活性成分和作用靶点，揭示葛根解酒的分子作用机制。方法：通过中药系统药理学数据库(TCMSP)检索葛根中所含的全部化学成分，以ADME参数(OB ≥ 30%和 DL ≥ 0.15)，筛选具有活性的化学成分，并查找活性化学成分对应的靶点蛋白，建立靶点数据集；使用Cytoscape3.6.1软件构建“活性成分–靶点–疾病”复杂网络关系图；通过生物学信息注释数据库(DAVID)进行GO生物功能富集分析和KEGG通路富集分析，探明葛根解酒的作用机制。结果：共检索出18个化合物，其中4个化学成分为活性化合物；共检索出92个作用靶点。通过网络拓扑特征评价，筛选出8个潜在作用靶点与葛根解酒的作用机制最为密切；利用DAVID数据库对潜在作用靶点进行基因GO功能富集分析和KEGG通路富集分析，筛选出35个生物过程和28条信号通路参与葛根解酒的作用。其中与葛根解酒较为密切的信号通路包括神经活性配体–受体相互作用、钙信号途径、胆碱能突触、心肌细胞中的肾上腺素信号、PI3K-AKT信号通路、VEGF信号通路、p53信号通路、NAFLD等信号通路，同时其主要涉及的生物过程包括雌二醇反应、突触传递、胆碱能、腺苷酸环化酶抑制G蛋白偶联乙酰胆碱受体信号通路、磷脂酶C激活G蛋白偶联乙酰胆碱受体信号通路、γ-氨基丁酸信号通路、RNA聚合酶II启动子转录的阳性调控作用、细胞色素c激活参与凋亡过程的半胱氨酸型内肽酶活性等，从而发挥多成分、多靶点、多途径解酒的生物学效应。结论：网络药理学为葛根解酒的作用机制提供了研究方向及科学依据。</p><p>关键词 :葛根，活性成分，解酒，网络药理学，作用机制</p><disp-formula id="hanspub.33860-formula44"><graphic xlink:href="//html.hanspub.org/file/3-1710207x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/3-1710207x8_hanspub.png" /> <img src="//html.hanspub.org/file/3-1710207x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>在全球范围内，酗酒是导致全球中青年死亡的主要风险因素之一 [<xref ref-type="bibr" rid="hanspub.33860-ref1">1</xref>]。在2016年，酒精中毒是死亡和DALYs (伤残调整生命年)的第七大风险因素，占死亡总数比例2.2% [<xref ref-type="bibr" rid="hanspub.33860-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.33860-ref3">3</xref>]。中国是全球饮酒致死人数最多的国家，饮酒不仅已成为全球性公共卫生健康问题，同时也是我国日益突出的社会问题 [<xref ref-type="bibr" rid="hanspub.33860-ref4">4</xref>]。急性酒精中毒是指由于一次性饮入过量的酒精或酒精类饮料引起的中枢神经系统由兴奋转为抑制的状态，也称为醉酒 [<xref ref-type="bibr" rid="hanspub.33860-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.33860-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.33860-ref7">7</xref>]。研究表明，虽然适度饮酒可降低死亡风险 [<xref ref-type="bibr" rid="hanspub.33860-ref8">8</xref>]，但是饮酒过度引起的健康问题与社会问题日益严重，且饮酒与多种疾病的发生机制皆有关联，例如心血管系统疾病、糖尿病、酒精性肝病(ALD)等 [<xref ref-type="bibr" rid="hanspub.33860-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.33860-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.33860-ref11">11</xref>]。葛根已被证明是非常有效的并且被广泛使用，目前在中国用于单独或联合解酒 [<xref ref-type="bibr" rid="hanspub.33860-ref12">12</xref>]。因此，进一步研究葛根对于解酒的分子机制起着至关重要的作用。</p><p>葛根(Pueraria lobata)为豆科植物野葛的干燥根，具有解肌退热、透疹、生津止渴、升阳止泻、通经活络、解酒毒之功效。临床上常用于治疗表证发热、项背强痛、麻疹不透、热病口渴、阴虚消渴等症 [<xref ref-type="bibr" rid="hanspub.33860-ref13">13</xref>]。葛根为药食两用植物 [<xref ref-type="bibr" rid="hanspub.33860-ref14">14</xref>]，历代医药著作常用于解酒的药用频率居诸药之首。据《神农本草经》、《汤液本草》、《本草拾遗》、《千金方》等本草著作记载；葛根能“治酒醉不醒”且“解酒毒尤良”。现代研究表明，葛根主要含有异黄酮及其苷类化合物(葛根素、大豆苷、大豆苷元等)、香豆素类及葛酚苷类化合物(拟雌内酯、葛香豆雌酚等)以及三萜类(葛根皂苷SA1、SB1、A1、C1等)等成分，而其“解酒毒”的主要成分为总黄酮类，体内动物实验研究也表明葛根解酒作用显著 [<xref ref-type="bibr" rid="hanspub.33860-ref15">15</xref>] - [<xref ref-type="bibr" rid="hanspub.33860-ref21">21</xref>]。研究表明，葛根解酒作用可通过在胃肠粘膜上形成保护膜而阻断人体对酒精的吸收，从而影响酒精吸收 [<xref ref-type="bibr" rid="hanspub.33860-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.33860-ref23">23</xref>] [<xref ref-type="bibr" rid="hanspub.33860-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.33860-ref25">25</xref>]，也可通过其异黄酮清除氧自由基和抗脂质过氧化损坏，从而发挥抗氧化作用，起到保肝健脑的作用 [<xref ref-type="bibr" rid="hanspub.33860-ref26">26</xref>]。目前，葛根产品的开发利用越来越丰富，如葛根保健饮料、葛粉、葛根面包等 [<xref ref-type="bibr" rid="hanspub.33860-ref27">27</xref>]。因此，探明葛根解酒的作用机制对其解酒的现代科学内涵具有十分重要的指导意义。虽然目前有关葛根解酒作用的药效研究比较集中，但从细胞及分子水平研究葛根解酒的作用机制相对比较缺乏。近年来，网络药理学整体性、系统性的特点与中药“多成分、多途径、多靶点”协同作用的特点不谋而合，为中医药复杂系统的研究提供了新的视角和思路 [<xref ref-type="bibr" rid="hanspub.33860-ref28">28</xref>] - [<xref ref-type="bibr" rid="hanspub.33860-ref33">33</xref>]。因此，本文采用网络药理学的方法，对葛根活性成分解酒的作用靶点及信号通路进行分析，以期探明葛根解酒的现代科学内涵，也为葛根的深入研究及开发利用提供参考依据。拟从分析葛根解酒的作用机制出发，建立完善的酒精中毒诊疗体系，通过预测其网络药理学作用靶点，从而揭示其解救急性酒精中毒的分子机制。</p></sec><sec id="s4"><title>2. 方法</title><sec id="s4_1"><title>2.1. 化学成分的建立</title><p>通过中药系统药理学分析平台(TCMSP) (http://lsp.nwu.edu.cn/tcmsp.php)，检索葛根所含的全部化学成分。TCMSP不仅是一个数据存储库，也是用户全面研究中药(TCM)的分析平台。将葛根放入TCMSP中，共得到16个分子，其中包括活性成分的鉴定，药物靶标的筛选和化合物–靶标–疾病网络的产生，以及详细的药物动力学信息涉及药物样(DL) Drug-likeness，口服生物利用度(OB) Oral bioavailability，血脑屏障(BBB) Blood-brain barrier，肠上皮通透性(Caco-2) Caco-2 permeability等。</p></sec><sec id="s4_2"><title>2.2. 活性成分的筛选</title><p>通过TCMSP数据库，以ADME参数(OB ≥ 30%和DL ≥ 0.15)为标准，筛选葛根的活性化学成分。</p></sec><sec id="s4_3"><title>2.3. 靶点的筛选与建立</title><p>通过TCMSP数据库，检索葛根活性成分对应的作用靶点，建立成分靶点数据集。再依据相似性比较，通过中草药活性成分数据库(HIT, http://lifecenter.sgst.cn/hit/)和治疗靶点数据库(TTD, http://bidd.nus.edu.sg/group/cjttd/)进行活性成分潜在靶点的筛选，建立葛根活性成分潜在靶点数据集，并通过人类基因和基因表型综合数据库(OMIM, http://www.omim.org/)筛选解酒的基因和蛋白靶点，建立解酒靶点数据集。人类的靶点连接蛋白通过交互蛋白数据库(http://dip.doe-mbi.ucla.edu)获得。最后将筛选得到的所有靶点均经UniProt数据库查询转化成UniProt ID格式，所有靶点涵盖了动物及人类靶点，所以需要使用UniProt数据库转化人类靶点，将动物靶点转化为与人类相关靶点。</p></sec><sec id="s4_4"><title>2.4. 网络构建与分析</title><p>通过PPI (http://www.genome.jp/kegg/)分析，将葛根的活性成分、成分对应的靶点、解酒对应的靶点和交互蛋白对应的靶点连接成“成分–靶点–疾病”网络。利用Cytoscape 3.6.1软件将以上网络进行可视化分析，得到每个节点的Degree、Betweenness centrality、Closeness centrality三个拓扑参数；通过CentiScaPe 1.2进行评估，得到葛根解酒的潜在靶点。</p></sec><sec id="s4_5"><title>2.5. 生物过程分析</title><p>将潜在靶点使用DAVID (https://david.ncifcrf.gov/)数据库进行KEGG通路分析和GO (Gene Ontology)生物学过程分析。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 活性成分的筛选</title><p>通过TCMSP数据库，检索得到18个葛根的化学成分，以ADME参数(OB ≥ 30%和DL ≥ 0.15)为标准，共筛选得到4个活性化合物，结果见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Kudzu root active compounds and target</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Mol ID</th><th align="center" valign="middle" >化学成分</th><th align="center" valign="middle" >靶标数目</th><th align="center" valign="middle" >OB (%)</th><th align="center" valign="middle" >DL</th></tr></thead><tr><td align="center" valign="middle" >MOL000392</td><td align="center" valign="middle" >formononetin</td><td align="center" valign="middle" >39</td><td align="center" valign="middle" >69.67</td><td align="center" valign="middle" >0.21</td></tr><tr><td align="center" valign="middle" >MOL000358</td><td align="center" valign="middle" >beta-sitosterol</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >36.91</td><td align="center" valign="middle" >0.75</td></tr><tr><td align="center" valign="middle" >MOL002959</td><td align="center" valign="middle" >3'-Methoxydaidzein</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >48.57</td><td align="center" valign="middle" >0.24</td></tr><tr><td align="center" valign="middle" >MOL003629</td><td align="center" valign="middle" >Daidzein-4,7-diglucoside</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >47.27</td><td align="center" valign="middle" >0.67</td></tr></tbody></table></table-wrap><p>表1. 葛根活性化合物及靶标数</p></sec><sec id="s5_2"><title>3.2. 药物靶点和疾病靶点数据的筛选</title><p>通过TCMSP数据库，共筛选得到92个葛根活性化学成分对应的作用靶点，结果见表1。通过OMIM数据库，查找得到49个解酒相关的靶点。通过网络药理学构建出葛根解酒作用的交互网络，采用不同颜色和形状图形使其可视化后，可直观的看出活性化学成分与疾病靶点之间的网络关系，结果见图1。其中，黄色方形代表药物与疾病的作用靶点，也是葛根解酒最重要的靶点蛋白；黄色圆点代表解酒直接作用靶点；红色三角形代表葛根中被预测出的活性化学成分；蓝色圆点代表葛根活性化学成分的直接作用靶点；紫色圆点代表连接葛根活性化学成分与疾病靶点的交互蛋白。</p><p>图1. 葛根解酒的“成分-靶点-疾病”交互网络</p></sec><sec id="s5_3"><title>3.3. 葛根解酒的直接作用靶点拓扑参数分析</title><p>通过Cytoscape 3.6.1软件进行交互网络分析，得到葛根活性成分相关联的蛋白靶点。通过计算得到网络中三个拓扑参数(Degree、Betweenness centrality和Closeness centrality)分别为：1.00、0和0.167。将上述筛选出的靶点作为葛根解酒的潜在靶点蛋白，共得到8个靶点满足以上条件，结果见表2。将潜在靶点蛋白进行蛋白相互关系分析，结果见图2。蛋白相互关系分析说明葛根解酒的潜在靶点蛋白相互关联和彼此调节。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Topological parameters related to the direct action target of Pueraria Radi</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Uniprot ID</th><th align="center" valign="middle" >Protein names</th><th align="center" valign="middle" >Gene names</th><th align="center" valign="middle" >Closeness Centrality</th><th align="center" valign="middle" >Degree</th><th align="center" valign="middle" >Betweeness Centrality</th></tr></thead><tr><td align="center" valign="middle" >P08172</td><td align="center" valign="middle" >Muscarinic acetylcholine receptor M2</td><td align="center" valign="middle" >CHRM2</td><td align="center" valign="middle" >0.28</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.00</td></tr><tr><td align="center" valign="middle" >P13569</td><td align="center" valign="middle" >Cystic fibrosis transmembrane conductance regulator</td><td align="center" valign="middle" >CFTR</td><td align="center" valign="middle" >0.22</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.01</td></tr><tr><td align="center" valign="middle" >P14416</td><td align="center" valign="middle" >D(2) dopamine receptor</td><td align="center" valign="middle" >DRD2</td><td align="center" valign="middle" >0.22</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.00</td></tr><tr><td align="center" valign="middle" >P21917</td><td align="center" valign="middle" >D(4) dopamine receptor</td><td align="center" valign="middle" >DRD4</td><td align="center" valign="middle" >0.22</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.01</td></tr><tr><td align="center" valign="middle" >P47869</td><td align="center" valign="middle" >Gamma-aminobutyric acid receptor subunit alpha-2</td><td align="center" valign="middle" >GABRA2</td><td align="center" valign="middle" >0.28</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0.00</td></tr><tr><td align="center" valign="middle" >Q01959</td><td align="center" valign="middle" >Sodium-dependent dopamine transporter</td><td align="center" valign="middle" >SLC6A3</td><td align="center" valign="middle" >0.00</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0.00</td></tr><tr><td align="center" valign="middle" >P31645</td><td align="center" valign="middle" >Sodium-dependent serotonin transporter</td><td align="center" valign="middle" >SLC6A4</td><td align="center" valign="middle" >0.36</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.01</td></tr><tr><td align="center" valign="middle" >V9HWC9</td><td align="center" valign="middle" >Superoxide dismutase [Cu-Zn]</td><td align="center" valign="middle" >HEL-S-44</td><td align="center" valign="middle" >0.00</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0.00</td></tr></tbody></table></table-wrap><p>表2. 葛根活性成分解酒的直接作用靶点相关拓扑参数</p><p>图2. 葛根解酒作用的潜在靶点蛋白相互关系图</p></sec><sec id="s5_4"><title>3.4. GO生物学功能分析</title><p>将8个潜在靶点映射到DAVID数据库中，进行生物学功能富集。GO富集分析，得到222个生物学进程、39个细胞组成和67个分子功能，其中P值 ≤ 0.001的生物进程共有35条，结果见表3。结果表明，这些靶点与多种生物进程相关，包括对雌二醇反应、突触传递、胆碱能、腺苷酸环化酶抑制G蛋白偶联乙酰胆碱受体信号通路、磷脂酶C激活G蛋白偶联乙酰胆碱受体信号通路、细胞色素c激活参与凋亡过程的半胱氨酸型内肽酶活性等，且这些生物进程可能与解酒的作用密切相关。同时揭示出了中药发挥药效作用涉及体内多个生物进程的调控。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Results of GO biological enrichment analysis of Pueraria hangover effec</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Category</th><th align="center" valign="middle" >Term</th><th align="center" valign="middle" >Count</th><th align="center" valign="middle" >Count%</th><th align="center" valign="middle" >P-Value</th></tr></thead><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >response to drug</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >18.5</td><td align="center" valign="middle" >1.8E−08</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >response to estradiol</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >12.3</td><td align="center" valign="middle" >5.2E−08</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >synaptic transmission, cholinergic</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >9.2</td><td align="center" valign="middle" >0.00000027</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >6.2</td><td align="center" valign="middle" >0.0000018</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >6.2</td><td align="center" valign="middle" >0.0000029</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >extrinsic apoptotic signaling pathway in absence of ligand</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >7.7</td><td align="center" valign="middle" >0.0000082</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >response to nicotine</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >7.7</td><td align="center" valign="middle" >0.000012</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >angiogenesis</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >12.3</td><td align="center" valign="middle" >0.000022</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >G-protein coupled acetylcholine receptor signaling pathway</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >6.2</td><td align="center" valign="middle" >0.000023</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >response to lipopolysaccharide</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >10.8</td><td align="center" valign="middle" >0.000037</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >response to hydrogen peroxide</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >7.7</td><td align="center" valign="middle" >0.000042</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >positive regulation of cell proliferation</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >15.4</td><td align="center" valign="middle" >0.000064</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >positive regulation of smooth muscle contraction</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >6.2</td><td align="center" valign="middle" >0.000067</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >positive regulation of transcription from RNA polymerase II promoter</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >21.5</td><td align="center" valign="middle" >0.000069</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >gamma-aminobutyric acid signaling pathway</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >6.2</td><td align="center" valign="middle" >0.000077</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >memory</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >7.7</td><td align="center" valign="middle" >0.000091</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >peptidyl-serine phosphorylation</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >9.2</td><td align="center" valign="middle" >0.00011</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >phospholipase C-activating G-protein coupled receptor signaling pathway</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >7.7</td><td align="center" valign="middle" >0.00012</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >positive regulation of transcription, DNA-templated</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >15.4</td><td align="center" valign="middle" >0.00014</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >behavioral fear response</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >6.2</td><td align="center" valign="middle" >0.00018</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >response to cobalt ion</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >4.6</td><td align="center" valign="middle" >0.00021</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >positive regulation of vasoconstriction</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >6.2</td><td align="center" valign="middle" >0.00024</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >transcription initiation from RNA polymerase II promoter</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >9.2</td><td align="center" valign="middle" >0.00028</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >response to toxic substance</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >7.7</td><td align="center" valign="middle" >0.00031</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >signal transduction</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >21.5</td><td align="center" valign="middle" >0.00037</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >peptidyl-threonine phosphorylation</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >6.2</td><td align="center" valign="middle" >0.0004</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >cell proliferation</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >12.3</td><td align="center" valign="middle" >0.00047</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >response to hypoxia</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >9.2</td><td align="center" valign="middle" >0.0005</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >4.6</td><td align="center" valign="middle" >0.00051</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >positive regulation of ERK1 and ERK2 cascade</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >9.2</td><td align="center" valign="middle" >0.00054</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >positive regulation of neuron apoptotic process</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >6.2</td><td align="center" valign="middle" >0.00058</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >positive regulation of nitric oxide biosynthetic process</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >6.2</td><td align="center" valign="middle" >0.00058</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >regulation of cell proliferation</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >9.2</td><td align="center" valign="middle" >0.00069</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >T cell activation</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >6.2</td><td align="center" valign="middle" >0.00076</td></tr><tr><td align="center" valign="middle" >GOTERM_BP_DIRECT</td><td align="center" valign="middle" >intrinsic apoptotic signaling pathway in response to DNA damage</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >6.2</td><td align="center" valign="middle" >0.00076</td></tr></tbody></table></table-wrap><p>表3. 葛根解酒作用的GO生物学功能富集分析结果</p></sec><sec id="s5_5"><title>3.5. KEGG通路分析</title><p>将8个潜在靶点映射到DAVID数据库中，进行KEGG通路富集分析，共得到76条信号通路，其中P值 ≤ 0.001的信号通路共有28条，结果见表4。其中神经活性配体–受体相互作用、钙信号途径、胆碱能突触、心肌细胞中的肾上腺素信号、PI3K-AKT信号通路等、VEGF信号通路、p53信号通路、NAFLD等信号通路可能直接或间接参与葛根解酒的作用。此结果与解酒机制可能紧密相关。同时利用KEGG信号通路数据库中的KEGG Mapper功能将8个葛根与解酒相关联的靶点蛋白，在与GABA能突触最为密切的信号通路上标注出来，结果显示有4个靶点蛋白参与GABA能突触信号通路的相关调控，结果见图3。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> KEGG pathway enrichment analysis of Pueraria hangover effec</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Category</th><th align="center" valign="middle" >Term</th><th align="center" valign="middle" >Count</th><th align="center" valign="middle" >Count %</th><th align="center" valign="middle" >P-Value</th></tr></thead><tr><td align="center" valign="middle" >KEGG_PATHWAY</td><td align="center" valign="middle" >Neuroactive ligand-receptor interaction</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >27.7</td><td align="center" valign="middle" >7.1E−11</td></tr><tr><td align="center" valign="middle" >KEGG_PATHWAY</td><td align="center" valign="middle" >Pathways in cancer</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >27.7</td><td align="center" valign="middle" >1.6E−08</td></tr><tr><td align="center" valign="middle" >KEGG_PATHWAY</td><td align="center" valign="middle" >Calcium signaling pathway</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >2.6E−08</td></tr><tr><td align="center" valign="middle" >KEGG_PATHWAY</td><td align="center" valign="middle" >Hepatitis B</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >16.9</td><td align="center" valign="middle" >3.3E−07</td></tr><tr><td align="center" valign="middle" >KEGG_PATHWAY</td><td align="center" valign="middle" >Cholinergic synapse</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >15.4</td><td align="center" valign="middle" >3.4E−07</td></tr><tr><td align="center" valign="middle" >KEGG_PATHWAY</td><td align="center" valign="middle" >Colorectal cancer</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >12.3</td><td align="center" valign="middle" >8.1E−07</td></tr><tr><td align="center" valign="middle" >KEGG_PATHWAY</td><td align="center" valign="middle" >Morphine addiction</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >13.8</td><td align="center" valign="middle" >8.8E−07</td></tr><tr><td align="center" valign="middle" >KEGG_PATHWAY</td><td align="center" valign="middle" >Thyroid hormone signaling pathway</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >13.8</td><td align="center" valign="middle" >0.0000052</td></tr><tr><td align="center" valign="middle" >KEGG_PATHWAY</td><td align="center" valign="middle" >Estrogen signaling pathway</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >12.3</td><td align="center" valign="middle" >0.000019</td></tr><tr><td align="center" valign="middle" >KEGG_PATHWAY</td><td align="center" valign="middle" >Retrograde endocannabinoid signaling</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >12.3</td><td align="center" valign="middle" >0.000022</td></tr><tr><td align="center" valign="middle" >KEGG_PATHWAY</td><td align="center" valign="middle" >Serotonergic synapse</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >12.3</td><td align="center" valign="middle" >0.00004</td></tr><tr><td align="center" valign="middle" >KEGG_PATHWAY</td><td align="center" valign="middle" >Small cell lung cancer</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >10.8</td><td align="center" valign="middle" >0.000079</td></tr><tr><td align="center" valign="middle" >KEGG_PATHWAY</td><td align="center" valign="middle" >Progesterone-mediated oocyte maturation</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >10.8</td><td align="center" valign="middle" >0.000091</td></tr><tr><td align="center" valign="middle" >KEGG_PATHWAY</td><td align="center" valign="middle" >Prostate cancer</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >10.8</td><td align="center" valign="middle" >0.000097</td></tr><tr><td align="center" valign="middle" >KEGG_PATHWAY</td><td align="center" valign="middle" >PI3K-Akt signaling pathway</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >18.5</td><td align="center" valign="middle" >0.00014</td></tr><tr><td align="center" valign="middle" >KEGG_PATHWAY</td><td align="center" valign="middle" >Adrenergic signaling in cardiomyocytes</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >12.3</td><td align="center" valign="middle" >0.00016</td></tr><tr><td align="center" valign="middle" >KEGG_PATHWAY</td><td align="center" valign="middle" >VEGF signaling pathway</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >9.2</td><td align="center" valign="middle" >0.00016</td></tr><tr><td align="center" valign="middle" >KEGG_PATHWAY</td><td align="center" valign="middle" >Apoptosis</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >9.2</td><td align="center" valign="middle" >0.00017</td></tr><tr><td align="center" valign="middle" >KEGG_PATHWAY</td><td align="center" valign="middle" >Amphetamine addiction</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >9.2</td><td align="center" valign="middle" >0.00023</td></tr><tr><td align="center" valign="middle" >KEGG_PATHWAY</td><td align="center" valign="middle" >p53 signaling pathway</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >9.2</td><td align="center" valign="middle" >0.00025</td></tr><tr><td align="center" valign="middle" >KEGG_PATHWAY</td><td align="center" valign="middle" >Non-alcoholic fatty liver disease (NAFLD)</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >12.3</td><td align="center" valign="middle" >0.00028</td></tr><tr><td align="center" valign="middle" >KEGG_PATHWAY</td><td align="center" valign="middle" >Viral carcinogenesis</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >13.8</td><td align="center" valign="middle" >0.00033</td></tr><tr><td align="center" valign="middle" >KEGG_PATHWAY</td><td align="center" valign="middle" >Toxoplasmosis</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >10.8</td><td align="center" valign="middle" >0.00033</td></tr><tr><td align="center" valign="middle" >KEGG_PATHWAY</td><td align="center" valign="middle" >Nicotine addiction</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >7.7</td><td align="center" valign="middle" >0.00035</td></tr><tr><td align="center" valign="middle" >KEGG_PATHWAY</td><td align="center" valign="middle" >Tuberculosis</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >12.3</td><td align="center" valign="middle" >0.00073</td></tr><tr><td align="center" valign="middle" >KEGG_PATHWAY</td><td align="center" valign="middle" >GABAergic synapse</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >9.2</td><td align="center" valign="middle" >0.00076</td></tr><tr><td align="center" valign="middle" >KEGG_PATHWAY</td><td align="center" valign="middle" >Salivary secretion</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >9.2</td><td align="center" valign="middle" >0.0008</td></tr><tr><td align="center" valign="middle" >KEGG_PATHWAY</td><td align="center" valign="middle" >Amyotrophic lateral sclerosis (ALS)</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >7.7</td><td align="center" valign="middle" >0.00084</td></tr></tbody></table></table-wrap><p>表4. 葛根解酒作用的KEGG通路富集分析结果</p><p>图3. 葛根活性成分潜在靶点在关键信号通路上的标注图</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>图4. 葛根解酒作用机制图</p><p>葛根是国家卫生部认定的药食两用中药，2005年被世界粮农组织推荐为第六大类粮食作物 [<xref ref-type="bibr" rid="hanspub.33860-ref34">34</xref>]。葛根中异黄酮类活性成分具有防醉酒，醒酒和对抗酒精肝损伤等作用 [<xref ref-type="bibr" rid="hanspub.33860-ref35">35</xref>] - [<xref ref-type="bibr" rid="hanspub.33860-ref42">42</xref>]，但其具体作用机制尚未完全阐明。随着基因、蛋白和代谢组学的发展，许多学者尝试用现代医学解释中药的作用机制。但由于葛根所含的化学成分比较复杂，难以系统全面的揭示其药效物质基础和作用机制，给葛根的深入研究带来了难题。近些年，网络药理学的兴起，为中药药效物质基础和作用机制的研究提供了新的思路和方法，也进一步推动了中医药的快速发展。因此，通过网络药理学揭示葛根解酒的作用机制非常有意义。如图4。</p><p>目前，有关葛根解酒作用机制的研究还不够全面，宋浩亮等 [<xref ref-type="bibr" rid="hanspub.33860-ref43">43</xref>] 分别给小鼠灌胃葛根素溶液和饮用酒后，观察各组小鼠醉酒潜伏期明显延长，睡眠时间显著缩短；同时各组小鼠体内SOD、MDA、GSH-PX、GSH发生异常变化，结果给药组能够接近于正常水平。Zhang等 [<xref ref-type="bibr" rid="hanspub.33860-ref44">44</xref>] 研究发现葛根素能明显改善肝纤维化症状，显著降低ALT和AST的表达，而碱性磷酸酶(ALP)与谷氨酰转移酶(GGT)无明显变化，肝脏星状细胞(hepatic stellate cells, HSC)的吞噬能力增强，bcl-2 mRNA表达下降；结果说明葛根素可通过恢复肝脏功能，激活HSC的吞噬能力，从而达到有效防治肝脏纤维化，发挥解酒的作用。</p><p>本文采用网络药理学的研究方法，筛选出35个生物过程和28条信号通路参与葛根解酒的作用。其中与解酒相关的主要信号通路包括神经活性配体–受体相互作用、钙信号途径、胆碱能突触、心肌细胞中的肾上腺素信号、PI3K-AKT信号通路、VEGF信号通路、p53信号通路、NAFLD等信号通路，同时其主要涉及的生物过程包括雌二醇反应、突触传递、胆碱能、腺苷酸环化酶抑制G蛋白偶联乙酰胆碱受体信号通路、磷脂酶C激活G蛋白偶联乙酰胆碱受体信号通路、γ–氨基丁酸信号通路、RNA聚合酶II启动子转录的阳性调控作用、细胞色素c激活参与凋亡过程的半胱氨酸型内肽酶活性等，从而发挥多成分、多靶点、多途径解酒的生物学效应。网络药理学通过预测葛根解酒的作用靶点及信号通路，以期为葛根的保健作用及深入研究提供参考依据。</p></sec><sec id="s7"><title>文章引用</title><p>陈郁郁,黄旭龙,罗 覃,谭 洋,邓先波,江 来,杨 慧,王祥培. 基于网络药理学探讨葛根解酒的作用机制Exploring the Mechanism of Gegen Hangover Based on Network Pharmacology[J]. 药物资讯, 2020, 09(01): 17-26. https://doi.org/10.12677/PI.2020.91003</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.33860-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Rehm, J., Room, R., Graham, K., et al. (2003) The Relationship of Average Volume of Alcohol Consumption and Pat-terns of Drinking to Burden of Disease: An Overview. Addiction, 98, 1209-1228. 
&lt;br&gt;https://doi.org/10.1046/j.1360-0443.2003.00467.x</mixed-citation></ref><ref id="hanspub.33860-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Sisay, M., Barac, A., Bensenor, I., et al. (2018) Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016. JAMA Oncology, 4, 1221-1227.</mixed-citation></ref><ref id="hanspub.33860-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Rehm, J., Room, R., Monteiro, M., et al. (2003) Alcohol as a Risk Factor for Global Burden of Dis-ease. European Addiction Research, 9, 157-164. &lt;br&gt;https://doi.org/10.1159/000072222</mixed-citation></ref><ref id="hanspub.33860-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">陈意飞, 郭明, 董世童, 等. 急性酒精中毒风险防范的现状与思考[J]. 中华卫生应急电子杂志, 2019, 5(1): 36-37.</mixed-citation></ref><ref id="hanspub.33860-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">王璐. 急诊科治疗急性酒精中毒的临床分析[J]. 世界最新医学信息文摘, 2019, 19(31): 87.</mixed-citation></ref><ref id="hanspub.33860-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">吴标, 邓婷. 急性酒精中毒急诊应用醒脑静辅助治疗的临床研究[J]. 心理月刊, 2019, 14(3): 158.</mixed-citation></ref><ref id="hanspub.33860-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">孔涛, 曹安国, 吕高强. 醒脑静联合纳洛酮在120急救中治疗酒精中毒疗效分析[J]. 当代医学, 2017, 23(21): 110-112.</mixed-citation></ref><ref id="hanspub.33860-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Fillmore, K.M., Kerr, W.C., Stockwell, T., Chikritzhs, T. and Bostrom, A. (2006) Moderate Alcohol Use and Reduced Mortality Risk: Systematic Error in Prospective Studies. Addiction Research &amp; Theory, 14, 101-132.  
&lt;br&gt;https://doi.org/10.1080/16066350500497983</mixed-citation></ref><ref id="hanspub.33860-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Ronksley, P.E., Brien, S.E., Turner, B.J., Mukamal, K.J. and Ghali, W.A. (2011) Association of Alcohol Consumption with Selected Cardiovascular Disease Outcomes: A Systematic Review and Meta-Analysis. British Medical Journal, 342, d671. &lt;br&gt;https://doi.org/10.1136/bmj.d671</mixed-citation></ref><ref id="hanspub.33860-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Howard, A.A., Arnsten, J.H. and Gourevitch, M.N. (2004) Effect of Alcohol Consumption on Diabetes Mellitus: A Systematic Review. Annals of Internal Medicine, 140, 211-219.  
&lt;br&gt;https://doi.org/10.7326/0003-4819-140-6-200403160-00011</mixed-citation></ref><ref id="hanspub.33860-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Naimi, T.S., Brown, D.W., Brewer, R.D., et al. (2005) Cardiovascular Risk Factors and Confounders among Nondrinking and Moderate-Drinking U.S. Adults. Ameri-can Journal of Preventive Medicine, 28, 369-373.  
&lt;br&gt;https://doi.org/10.1016/j.amepre.2005.01.011</mixed-citation></ref><ref id="hanspub.33860-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Ding, R.-B., Tian, K., Huang, L.-L., et al. (2012) Herbal Medi-cines for the Prevention of Alcoholic Liver Disease: A Review. Journal of Ethnopharmacology, 144, 457-465. &lt;br&gt;https://doi.org/10.1016/j.jep.2012.09.044</mixed-citation></ref><ref id="hanspub.33860-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">中国药典[S]. 2015版. 一部. 2015: 333.</mixed-citation></ref><ref id="hanspub.33860-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">吕生波, 李海洲, 陈正余, 等. 葛根复合解酒固体饮料的研制[J]. 安康学院学报, 2016, 12, 8(6): 104-106.</mixed-citation></ref><ref id="hanspub.33860-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">张恩户, 赵勤, 梁作封, 等. 葛根总黄酮解酒作用的实验观察[J]. 陕西中医学院学报, 1995, 18(3): 38.</mixed-citation></ref><ref id="hanspub.33860-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">王庆端, 江金花, 孙文欣, 等. 葛根总黄酮的抗啤酒中枢抑制作用[J]. 河南医科大学学报, 1998, 33(3): 117-118.</mixed-citation></ref><ref id="hanspub.33860-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">叶丽, 丁慧琴. 葛根活性成分的药理作用及其现代临床应用[J]. 临床医药文献杂志, 2017, 4(32): 6273-6274.</mixed-citation></ref><ref id="hanspub.33860-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">张瑞婷, 周涛, 宋潇潇, 等. 葛根的活性成分及其药理作用研究进展[J]. 安徽农学通报, 2018, 24(1): 15-17.</mixed-citation></ref><ref id="hanspub.33860-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">周吉银, 周世文. 葛根总黄酮及葛根素解酒的药理研究进展[J]. 中国医院药学杂志, 2007, 27(9): 1280-1282.</mixed-citation></ref><ref id="hanspub.33860-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">张蓉蓉, 吴大正. 野葛解酒机制的研究进展[J]. 上海中医药大学学报, 2007, 21(2): 80-83.</mixed-citation></ref><ref id="hanspub.33860-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">欧阳玉祝, 朱露, 李雪峰. 响应面优化葛根总黄酮的钙离子沉淀分离工艺[J]. 食品科学, 2014, 35(4): 35-38.</mixed-citation></ref><ref id="hanspub.33860-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Lin, R.C. and Li, T.K. (1998) Effects of Isoflavones on Alcohol Pharmacokinetics and Alcohol-Drinking Behavior in Rats. The American Journal of Clinical Nutrition, 68, 1512S-1515S. &lt;br&gt;https://doi.org/10.1093/ajcn/68.6.1512S</mixed-citation></ref><ref id="hanspub.33860-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Xie, C.I., Lin, R.C., Antony, V., et al. (1994) Daidzin, an Antioxidant Isoflavonoid, Decreases Blood Alcohol Levels and Shortens Sleep Time Induced Byethanol Intoxication. Alcoholism: Clinical and Experimental Research, 18, 1443-1447. &lt;br&gt;https://doi.org/10.1111/j.1530-0277.1994.tb01448.x</mixed-citation></ref><ref id="hanspub.33860-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Shin, B.S., Jun, H., Lee, D.E., et al. (2005) Altered Oral Absorption of Alcohol Bycombined Aqueous Extracts of Four Herbal Plants in Rats. Journal of Toxicology and Envi-ronmental Health, Part A, 68, 2219-2226.  
&lt;br&gt;https://doi.org/10.1080/15287390500182081</mixed-citation></ref><ref id="hanspub.33860-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">王恒禹, 刘玥, 沈孝坤, 姜猛, 丁侃. 葛根的解酒作用及应用[J]. 中国医疗前沿, 2012, 7(20): 7-9.</mixed-citation></ref><ref id="hanspub.33860-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">刘青, 周金海. 葛根的临床应用[J]. 中国临床医生, 2003, 31(2): 55.</mixed-citation></ref><ref id="hanspub.33860-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">江立虹. 葛根开发现状及前景分析[J]. 中国林副特产, 2004, 73(6): 59-60.</mixed-citation></ref><ref id="hanspub.33860-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">程彬峰, 侯媛媛, 姜民, 等. 基于网络药理学的清肺消炎丸抗炎机制的初步研究[J]. 药学学报, 2013, 48(5): 686-693.</mixed-citation></ref><ref id="hanspub.33860-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">张立虎, 李冬冬, 萧伟, 等. 基于网络药理学与分子对接法预测银杏叶提取物的抗炎机制[J]. 中国实验方剂学杂志, 2018, 24(7): 192-198.</mixed-citation></ref><ref id="hanspub.33860-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">刘志华, 孙晓波. 网络药理学: 中医药现代化的新机遇[J]. 药学学报, 2012, 47(6): 696-703.</mixed-citation></ref><ref id="hanspub.33860-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Li, S. and Zhang, B. (2013) Traditional Chinese Medicine Network Pharmacology: Theory, Methodology and Application. Chinese Journal of Natural Medicines, 11, 110-120. &lt;br&gt;https://doi.org/10.1016/S1875-5364(13)60037-0</mixed-citation></ref><ref id="hanspub.33860-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, A., Sun, H., Yang, B. and Wang, X. (2012) Predict-ing New Molecular Targets for Rhein Using Network Pharmacology. BMC Systems Biology, 6, 20. &lt;br&gt;https://doi.org/10.1186/1752-0509-6-20</mixed-citation></ref><ref id="hanspub.33860-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">夏聪敏, 许波, 李刚, 等. 基于网络药理学探讨桂枝芍药知母汤治疗骨性关节炎的分子机制[J]. 中华中医药学刊, 2018, 36(11): 2681-2684.</mixed-citation></ref><ref id="hanspub.33860-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">刘小玲, 丘华, 王士长. 葛根功能饮料的制造[J]. 食品工业, 2001, 22(2): 18-19.</mixed-citation></ref><ref id="hanspub.33860-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">章文炽, 夏培源. 枳葛饮解酒作用的实验观察[J]. 中国医院药学杂志, 1994, 14(3): 137.</mixed-citation></ref><ref id="hanspub.33860-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">詹纯列, 李权超, 徐本法, 等. 新型醒酒糖作用的研究[J]. 中国实验方剂学杂志, 2000, 6(1): 30.</mixed-citation></ref><ref id="hanspub.33860-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">毕业东, 郭富成, 张德祥. 葛柏解酒液防治小鼠急性酒精中毒作用机制的实验研究[J]. 江西中医学院学报, 2005, 17(5): 50.</mixed-citation></ref><ref id="hanspub.33860-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">杨牧祥, 王志波, 于文涛, 等. 中药酒速愈对急性酒精中毒小鼠肝脏氧化酶的影响[J]. 中国中西医结合急救杂志, 2006, 13(3): 162.</mixed-citation></ref><ref id="hanspub.33860-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">吴贤生, 余庆涛, 葛亚中, 等. 葛根枳椇子栀子胶囊的解酒作用及其机制研究[J]. 湖南中医杂志, 2016, 32(11): 160-172.</mixed-citation></ref><ref id="hanspub.33860-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">张建夫, 陈亚红, 黄香丽, 等. 葛根与葛花解酒的功效研究[J]. 安徽农业科学, 2009, 37(35): 17505-17506.</mixed-citation></ref><ref id="hanspub.33860-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">王煜, 周吉银, 周世文. 含葛根解酒方剂的机制研究进展[J]. 中国药房, 2007, 18(18): 1424-1426.</mixed-citation></ref><ref id="hanspub.33860-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">杨牧祥, 田元祥, 姚树坤, 等. 解酒护肝饮对酒精性肝损伤大鼠血清和肝组织MDA、GSH的影响[J]. 河北中医药学报, 2000, 15(4): 1-5+14.</mixed-citation></ref><ref id="hanspub.33860-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">宋浩亮, 陈士林, 黄梦雨, 等. 葛根素对醉酒小鼠行为及抗氧化作用的研究[J]. 现代中药研究与实践, 2003, 17(3): 36-38.</mixed-citation></ref><ref id="hanspub.33860-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, S., Ji, G. and Liu, J. (2006) Reversal of Chemical-Induced Liver Fibrosis in Wistar Rats by Puerarin. The Journal of Nutritional Biochemistry, 17, 485-491. &lt;br&gt;https://doi.org/10.1016/j.jnutbio.2005.09.002</mixed-citation></ref></ref-list></back></article>